Retrospective analysis uncovers key factors influencing somatostatin receptor expression and PRRT prospects in metastatic neuroendocrine neoplasms.
Key Points
Mathematical models estimated somatostatin receptor expression accurately in 70-83% of cases, highlighting their effectiveness in predicting eligibility for therapy.
Key factors influencing treatment suitability included tumor origin, immunohistochemical markers, and clinical parameters such as age and disease extent.
SPECT/CT imaging showed strong potential in evaluating somatostatin receptor expression across 392 lesions, with notable correlations in metastatic sites.
Certain laboratory parameters could enhance individualised treatment strategies, indicating the potential for improved patient outcomes in neuroendocrine neoplasms.